<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPP</journal-id>
<journal-id journal-id-type="hwp">sptpp</journal-id>
<journal-title>Therapeutic Advances in Psychopharmacology</journal-title>
<issn pub-type="ppub">2045-1253</issn>
<issn pub-type="epub">2045-1261</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2045125312469982</article-id>
<article-id pub-id-type="publisher-id">10.1177_2045125312469982</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Methadone, QTc interval prolongation and <italic>torsade de pointes</italic>: Case reports offer the best understanding of this problem</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vieweg</surname><given-names>W. Victor R.</given-names></name>
<aff id="aff1-2045125312469982">Departments of Psychiatry and Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Hasnain</surname><given-names>Mehrul</given-names></name>
<aff id="aff2-2045125312469982">Department of Psychiatry, Memorial University, St John’s, Newfoundland, Canada</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Howland</surname><given-names>Robert H.</given-names></name>
<aff id="aff3-2045125312469982">University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Clausen</surname><given-names>Thomas</given-names></name>
<aff id="aff4-2045125312469982">Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Koneru</surname><given-names>Jayanthi N.</given-names></name>
<aff id="aff5-2045125312469982">Department of Internal Medicine, Division of Cardiology and Cardiac Electrophysiology, Virginia Commonwealth University, Richmond, Virginia, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Kogut</surname><given-names>Christopher</given-names></name>
<aff id="aff6-2045125312469982">Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Crouse</surname><given-names>Ericka L. Breden</given-names></name>
<aff id="aff7-2045125312469982">Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Hancox</surname><given-names>Jules C.</given-names></name>
<aff id="aff8-2045125312469982">School of Physiology and Pharmacology and Cardiovascular Research Laboratories, Medical Sciences Building, University of Bristol, University Walk, Bristol BS8 1TD, UK</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Fernandez</surname><given-names>Antony</given-names></name>
<aff id="aff9-2045125312469982">Departments of Psychiatry and Virginia Commonwealth University and Mental Health Service Line, Veterans Administration Medical Center, Richmond, Virginia, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Pandurangi</surname><given-names>Ananda K.</given-names></name>
<aff id="aff10-2045125312469982">Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2045125312469982"><email>VicVieweg@GMail.Com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>3</volume>
<issue>4</issue>
<fpage>219</fpage>
<lpage>232</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We reviewed the literature and found 31 adult cases and 1 newborn case of methadone-associated QTc interval prolongation and/or <italic>torsade de pointes</italic> (<italic>TdP</italic>). Parametric statistics may not be useful in studying this issue because methadone-associated <italic>TdP</italic> is a very rare event and, hence, “an extreme outlier” consistent with scalable randomness. We may have to rely upon narrative medicine in the form of case reports with all its limitations and hazards to provide our best understanding. We report risk factors for methadone-associated QTc interval prolongation and <italic>TdP</italic> based on review of published case reports. We believe both drug manufacturers and the FDA would better serve our patients and inform clinicians if they more readily reported drug-induced outliers such as methadone-associated <italic>TdP</italic> using a case report format.</p>
</abstract>
<kwd-group>
<kwd>Drug-induced QTc interval prolongation</kwd>
<kwd>methadone</kwd>
<kwd>risk factors</kwd>
<kwd><italic>torsade de pointes</italic></kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2045125312469982" sec-type="intro">
<title>Introduction</title>
<p>Our major aim is to identify risk factors for methadone-associated QTc interval prolongation and <italic>torsade de pointes</italic> (<italic>TdP</italic>) applying principles of narrative medicine in a case report format. Although drug-induced QTc interval prolongation may be a necessary precondition for methadone-induced/associated <italic>TdP</italic>, we argue that it is insufficient to explain <italic>TdP</italic>. We believe that the mix of biochemical/metabolic disturbances, genetic variation and structural changes combined with methadone-induced/associated QTc interval prolongation best explain <italic>TdP</italic>.</p>
<sec id="section2-2045125312469982">
<title>Methadone</title>
<p>Methadone is a synthetic opiate most commonly employed in addiction treatment (or <italic>opiate dependence</italic>) and pain management. In 2006, Drug and Alcohol Services Information System reported that in 2005, 235,836 persons received methadone either for opiate detoxification or maintenance [<xref ref-type="bibr" rid="bibr20-2045125312469982">Drug and Alcohol Services Information System, 2006</xref> <ext-link ext-link-type="uri" xlink:href="http://www.oas.samhsa.gov/2k6/otp/otp.htm">http://www.oas.samhsa.gov/2k6/otp/otp.htm</ext-link>]. Methadone’s primary mechanism of action is as a mu-receptor agonist that may work as an antagonist at the NMDA receptor [<xref ref-type="bibr" rid="bibr6-2045125312469982">Anderson <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr60-2045125312469982">Roxane Laboratories, 2003</xref>]. Methadone is lipophilic and has unpredictable pharmacokinetics with large patient variability in absorption, bioavailability, peak concentration and half-life. Its bioavailability can range from 36 to 100% and its half-life from 8 to 59 hours. Its duration of action may be prolonged due to its lipophilicity and ability to remain in the liver and other tissues [<xref ref-type="bibr" rid="bibr60-2045125312469982">Roxane Laboratories, 2003</xref>].</p>
</sec>
<sec id="section3-2045125312469982">
<title>hERG liability of methadone</title>
<p>A striking feature of drug-induced QTc interval prolongation and <italic>TdP</italic> is that virtually all clinically used drugs linked with these effects share in common an ability to inhibit channels that mediate the cardiac rapid delayed rectifier current, I<sub>Kr</sub>—an ionic current that is important in regulating ventricular action potential duration [<xref ref-type="bibr" rid="bibr78-2045125312469982">Witchel <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr27-2045125312469982">Hancox <italic>et al</italic>. 2008</xref>]. <italic>Human Ether-à-go-go-Related Gene (hERG)</italic> encodes a protein (hERG) that mediates I<sub>Kr</sub> [<xref ref-type="bibr" rid="bibr62-2045125312469982">Sanguinetti <italic>et al</italic>. 1995</xref>; <xref ref-type="bibr" rid="bibr68-2045125312469982">Trudeau <italic>et al</italic>. 1995</xref>]. Due to identified structural features, hERG exhibits a high susceptibility to pharmacological blockade [<xref ref-type="bibr" rid="bibr63-2045125312469982">Sanguinetti <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr27-2045125312469982">Hancox <italic>et al</italic>. 2008</xref>]. Similar to QTc prolongation, I<sub>Kr</sub>/hERG blockade is a surrogate marker of <italic>TdP</italic> rather than a direct indicator of arrhythmogenicity; it is likely that it is the downstream consequences of I<sub>Kr</sub> block, such as cellular early-after-depolarisations and augmented transmural dispersion of repolarisation that contribute to the genesis of <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr27-2045125312469982">Hancox <italic>et al</italic>. 2008</xref>]. Consequently, in preclinical drug safety testing any identified hERG-blocking tendency of an investigational drug (typically assessed through the study of hERG channels expressed in mammalian cell lines) must be considered alongside other preclinical information [<xref ref-type="bibr" rid="bibr25-2045125312469982">Gintant, 2008</xref>; <xref ref-type="bibr" rid="bibr27-2045125312469982">Hancox <italic>et al</italic>. 2008</xref>]. Analysis of the association between hERG/I<sub>Kr</sub> block and observed propensity of clinically used drugs to produce <italic>TdP</italic> has led to the recommendation of a provisional ‘safety margin’ for drugs undergoing evaluation based on the ratio of hERG/I<sub>Kr</sub> half-maximal inhibitory concentration (IC<sub>50</sub>) and effective therapeutic plasma concentration (ETPC, unbound) [<xref ref-type="bibr" rid="bibr57-2045125312469982">Redfern <italic>et al</italic>. 2003</xref>]. A 30-fold IC<sub>50</sub>/ETPC safety margin has been suggested to be sufficient for most drugs, although it is recognised that mixed ion channel block can mitigate risk [<xref ref-type="bibr" rid="bibr57-2045125312469982">Redfern <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr25-2045125312469982">Gintant, 2008</xref>; <xref ref-type="bibr" rid="bibr27-2045125312469982">Hancox <italic>et al</italic>. 2008</xref>].</p>
<p>In 1986, high concentrations of methadone were reported to slow depolarization rate and prolong duration of action potentials from sheep Purkinje fibers [<xref ref-type="bibr" rid="bibr46-2045125312469982">Mantelli <italic>et al</italic>. 1986</xref>]. Methadone and its relative L-α-acetylmethadol (LAAM) were later (in 2002) reported to inhibit hERG, with respective IC<sub>50</sub> values of 9.8 and 2.2 µM [<xref ref-type="bibr" rid="bibr34-2045125312469982">Katchman <italic>et al</italic>. 2002</xref>]. This study also related the observed IC<sub>50</sub> values to maximal plasma concentrations (<italic>C</italic>max) following therapeutic drug administration, obtaining IC<sub>50</sub>/<italic>C</italic>max ratios of 2.7 and 2.2 respectively for methadone and LAAM [<xref ref-type="bibr" rid="bibr34-2045125312469982">Katchman <italic>et al</italic>. 2002</xref>] hERG channel blockade by methadone and LAAM has been confirmed by a number of subsequent studies with reported IC<sub>50</sub> values for methadone ranging between ~1.7 and 20 µM [<xref ref-type="bibr" rid="bibr32-2045125312469982">Kang <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr35-2045125312469982">Kornick <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr21-2045125312469982">Eap <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr42-2045125312469982">Lin <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr82-2045125312469982">Zunkler <italic>et al</italic>. 2010</xref>]. Examination of the effects of these agents on other cardiac ion channels has suggested preferential block of hERG [<xref ref-type="bibr" rid="bibr32-2045125312469982">Kang <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>] with some effects of methadone evident also on hNav1.5 and hCav1.2[<xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>] and with much weaker effects on other cardiac K<sup>+</sup> currents [<xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>] indicating that hERG/I<sub>Kr</sub> K<sup>+</sup> channels are those most likely to be linked to methadone-induced QT prolongation. This is consistent with <italic>in vitro</italic> data indicating methadone-induced prolongation of the QT interval of isolated perfused rabbit hearts[<xref ref-type="bibr" rid="bibr33-2045125312469982">Katchman <italic>et al</italic>. 2006</xref>] and of action potentials from human stem-cell derived cardiomyocytes [<xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>]. The link between I<sub>Kr</sub>/hERG and methadone-induced QT prolongation is supported by observations regarding stereoselective actions of methadone enantiomers [<xref ref-type="bibr" rid="bibr21-2045125312469982">Eap <italic>et al</italic>. 2007</xref>, <xref ref-type="bibr" rid="bibr42-2045125312469982">Lin <italic>et al</italic>. 2009</xref>]. Two independent studies have shown (S)-methadone to be more potent against hERG than is (R)-methadone [<xref ref-type="bibr" rid="bibr21-2045125312469982">Eap <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr42-2045125312469982">Lin <italic>et al</italic>. 2009</xref>] with IC<sub>50</sub> values for hERG current block of 2 and 7 µM respectively [<xref ref-type="bibr" rid="bibr21-2045125312469982">Eap <italic>et al</italic>. 2007</xref>]. This correlates with reported observations: (i) that replacing (R,S) methadone with (R) methadone in patients receiving maintenance treatment reduces the QTc interval[<xref ref-type="bibr" rid="bibr7-2045125312469982">Ansermot <italic>et al</italic>. 2010</xref>] and (ii) that CYP2B6 slow metabolizer status (which leads to impaired (S)-methadone metabolism) correlates with a higher QTc interval in patients receiving racemic methadone than is the case for extensive metabolizers [<xref ref-type="bibr" rid="bibr21-2045125312469982">Eap <italic>et al</italic>. 2007</xref>] I<sub>Kr</sub>/hERG block by methadone may also be consistent with modestly increased QT-dispersion seen in some methadone-treated patients [<xref ref-type="bibr" rid="bibr36-2045125312469982">Krantz <italic>et al</italic>. 2005</xref>].</p>
<p>The original report of hERG channel block by methadone and LAAM included comparison with other opioid agonists, with fentanyl and buprenorphine also exhibiting hERG block with IC<sub>50</sub> values &lt; 10 µM, while codeine and morphine had little or no effect at therapeutically relevant concentrations [<xref ref-type="bibr" rid="bibr34-2045125312469982">Katchman <italic>et al</italic>. 2002</xref>]. However, normalization of data to IC<sub>50</sub>/<italic>C</italic>max values yielded only low values (&lt;3) for methadone and LAAM, with values of &gt;50 for other agents studied [<xref ref-type="bibr" rid="bibr34-2045125312469982">Katchman <italic>et al</italic>. 2002</xref>]. A separate study has compared methadone and heroin effects on hERG, reporting the latter to be ~100-fold less potent than methadone [<xref ref-type="bibr" rid="bibr82-2045125312469982">Zunkler <italic>et al</italic>. 2010</xref>]. Chlorobutanol has been suggested to potentiate the ability of methadone to inhibit hERG current [<xref ref-type="bibr" rid="bibr35-2045125312469982">Kornick <italic>et al</italic>. 2003</xref>] and diazepam has been suggested to exacerbate hERG-blocking effects of methadone by alleviating methadone block of sodium channels and, thereby, reducing any compensatory effect of sodium channel block on hERG inhibition [<xref ref-type="bibr" rid="bibr41-2045125312469982">Kuryshev <italic>et al</italic>. 2010</xref>].</p>
</sec>
</sec>
<sec id="section4-2045125312469982" sec-type="cases">
<title>Case report format</title>
<p>Rather than attempting to develop a database that can be analyzed using parametric statistics, we employed the principles of narrative medicine in a case report format as we have in our other papers assessing psychotropic drug-induced QTc interval prolongation and <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr70-2045125312469982">Vieweg, 2003</xref>; <xref ref-type="bibr" rid="bibr73-2045125312469982">Vieweg <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr72-2045125312469982">Vieweg <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr69-2045125312469982">Vieweg <italic>et al</italic>. 2012</xref>]. Data from our review of case reports in the literature and analyses of those data form the body of our paper.</p>
</sec>
<sec id="section5-2045125312469982" sec-type="methods">
<title>Methods</title>
<p>On January 8, 2012, we entered “methadone and QT prolongation” (81 articles), “methadone and QTc” (71 articles) and then “methadone and <italic>torsade</italic>” (38 articles) into PubMed limiting our selections to those in English. From these findings, we found 20 case reports in the literature and 12 additional case reports referenced in this literature (one was not in English).</p>
</sec>
<sec id="section6-2045125312469982" sec-type="results">
<title>Results</title>
<p>Vital information from these 32 case reports appears in <xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>. Nineteen subjects were men (age 44.4±12.9, range 22-61 years). Twelve subjects were women (age 46.3±7.0, range 36-61 years). One subject was a female newborn.</p>
<table-wrap id="table1-2045125312469982" position="float">
<label>Table 1.</label>
<caption>
<p>Case report risk factors for QTc interval prolongation and <italic>torsade de pointes</italic> (<italic>TdP</italic>) Cases in red formed the 21 patients allowing a correlation between QTc interval prolongation and methadone dose. Based on current evidence reviewed in this paper, risk factors in addition to methadone are tabulated and include (1) female sex [<italic>n</italic>=12], (2) heart disease [<italic>n</italic>=11], (3) electrolyte imbalance [hypokalemia (<italic>n</italic>=7) and hypomagnesemia (<italic>n</italic>=4)], (4) metabolic drug interactions [CYP inhibitors (CYP) [<italic>n</italic>=19], (5) concurrent use of medications associated with QTc interval prolongation [QTc prolonging (QTP) [<italic>n</italic>=14], (6) hepatic impairment [<italic>n</italic>=6] and (7) other risk factors: bradycardia [<italic>n</italic>=8][<xref ref-type="bibr" rid="bibr11-2045125312469982">Brachmann <italic>et al</italic>. 1983</xref>] and cocaine [<italic>n</italic>=6][<xref ref-type="bibr" rid="bibr44-2045125312469982">Magnano <italic>et al</italic>. 2006</xref>].</p>
</caption>
<graphic alternate-form-of="table1-2045125312469982" xlink:href="10.1177_2045125312469982-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Case &amp; Citation</th>
<th align="center">QTc msec</th>
<th align="center">Methadone<break/>mg/day</th>
<th align="center"><italic>TdP</italic></th>
<th align="center">Age Years</th>
<th align="center">Sex M/F</th>
<th align="center">Heart<break/>disease</th>
<th align="center">Electrolytes imbalance<break/>↓K, ↓Mg</th>
<th align="center">Interacting drugs<break/>CYP inhibitors (CYP)<break/>QTc prolonging (QTP)</th>
<th align="center">Hepatic impairment</th>
<th align="center">Other risk factors</th>
<th align="center">Total<break/>#</th>
</tr>
</thead>
<tbody>
<tr>
<td>1[<xref ref-type="bibr" rid="bibr18-2045125312469982">Deamer <italic>et al</italic>. 2001</xref>]</td>
<td>710</td>
<td>120</td>
<td>Yes</td>
<td>41</td>
<td>F</td>
<td/>
<td>↓Mg</td>
<td>Cannabinoids (CYP3A4), Fluoxetine (CYP2D6, CYP2C19, CYP3A4, QTP)</td>
<td/>
<td/>
<td>5</td>
</tr>
<tr>
<td>2[<xref ref-type="bibr" rid="bibr77-2045125312469982">Walker <italic>et al</italic>. 2003</xref>]</td>
<td>Prolonged</td>
<td>660</td>
<td>Yes</td>
<td>41</td>
<td>F</td>
<td/>
<td>↓K</td>
<td>Fluoxetine (CYP2D6, CYP2C19, CYP3A4, QTP)</td>
<td/>
<td/>
<td>4</td>
</tr>
<tr>
<td>3[<xref ref-type="bibr" rid="bibr77-2045125312469982">Walker <italic>et al</italic>. 2003</xref>]</td>
<td>Prolonged</td>
<td>650</td>
<td>Yes</td>
<td>52</td>
<td>F</td>
<td>Yes</td>
<td/>
<td/>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>4[<xref ref-type="bibr" rid="bibr77-2045125312469982">Walker <italic>et al</italic>. 2003</xref>]</td>
<td>Prolonged</td>
<td>700</td>
<td>Yes</td>
<td>61</td>
<td>F</td>
<td>Yes</td>
<td/>
<td>Sertraline (CYP2B6, CYP2C19)</td>
<td/>
<td/>
<td>3</td>
</tr>
<tr>
<td>5[<xref ref-type="bibr" rid="bibr76-2045125312469982">Vodoz <italic>et al</italic>. 2003</xref>]</td>
<td>Prolonged</td>
<td>200</td>
<td>Yes</td>
<td>25</td>
<td>M</td>
<td>Yes</td>
<td/>
<td/>
<td/>
<td/>
<td>1</td>
</tr>
<tr>
<td>6[<xref ref-type="bibr" rid="bibr24-2045125312469982">Gil <italic>et al</italic>. 2003</xref>]</td>
<td>600</td>
<td>275</td>
<td>Yes</td>
<td>36</td>
<td>M</td>
<td>Yes</td>
<td/>
<td>Cotrimoxazole (CYP3A4, QTP)</td>
<td/>
<td/>
<td>3</td>
</tr>
<tr>
<td>7[<xref ref-type="bibr" rid="bibr24-2045125312469982">Gil <italic>et al</italic>. 2003</xref>]</td>
<td>640</td>
<td>300</td>
<td>Yes</td>
<td>39</td>
<td>M</td>
<td>Yes</td>
<td/>
<td>Clarithromycin (CYP3A4, QTP)</td>
<td/>
<td>Sinus bradycardia</td>
<td>4</td>
</tr>
<tr>
<td>8[<xref ref-type="bibr" rid="bibr24-2045125312469982">Gil <italic>et al</italic>. 2003</xref>]</td>
<td>640</td>
<td>385</td>
<td>?</td>
<td>34</td>
<td>M</td>
<td/>
<td/>
<td/>
<td/>
<td>Sinus bradycardia</td>
<td>1</td>
</tr>
<tr>
<td>9[<xref ref-type="bibr" rid="bibr24-2045125312469982">Gil <italic>et al</italic>. 2003</xref>]</td>
<td>510</td>
<td>700</td>
<td>Yes</td>
<td>31</td>
<td>M</td>
<td>Yes</td>
<td/>
<td>Cotrimoxazole (CYP3A4, QTP), Foscarnet (QTP)</td>
<td/>
<td/>
<td>4</td>
</tr>
<tr>
<td>10[<xref ref-type="bibr" rid="bibr3-2045125312469982">Almehmi <italic>et al</italic>. 2004</xref>]</td>
<td>549</td>
<td>700</td>
<td>Yes</td>
<td>51</td>
<td>M</td>
<td/>
<td>↓K<break/>↓Mg</td>
<td/>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>11[<xref ref-type="bibr" rid="bibr39-2045125312469982">Krantz <italic>et al</italic>. 2005</xref>]</td>
<td>582</td>
<td>450</td>
<td>Yes</td>
<td>42</td>
<td>M</td>
<td/>
<td/>
<td>Fluvoxamine (CYP3A4)</td>
<td/>
<td/>
<td>1</td>
</tr>
<tr>
<td>12[<xref ref-type="bibr" rid="bibr40-2045125312469982">Krantz <italic>et al</italic>. 2005</xref>]</td>
<td>635</td>
<td>80</td>
<td>Yes</td>
<td>46</td>
<td>F</td>
<td>Yes</td>
<td>↓K</td>
<td/>
<td/>
<td>Cocaine</td>
<td>4</td>
</tr>
<tr>
<td>13[<xref ref-type="bibr" rid="bibr43-2045125312469982">Lüthi <italic>et al</italic>. 2007</xref>]</td>
<td>654</td>
<td>150</td>
<td>Yes</td>
<td>53</td>
<td>F</td>
<td/>
<td>↓K<break/>↓Mg</td>
<td/>
<td>Yes</td>
<td/>
<td>4</td>
</tr>
<tr>
<td>14[<xref ref-type="bibr" rid="bibr59-2045125312469982">Routhier <italic>et al</italic>. 2007</xref>]</td>
<td>517</td>
<td>145</td>
<td>Yes</td>
<td>52</td>
<td>F</td>
<td>Yes</td>
<td>↓K</td>
<td/>
<td>Yes</td>
<td>Cocaine</td>
<td>5</td>
</tr>
<tr>
<td>15[<xref ref-type="bibr" rid="bibr29-2045125312469982">Hussain <italic>et al</italic>. 2007</xref>]</td>
<td>510</td>
<td>In utero exposure</td>
<td>No</td>
<td>0</td>
<td>F<xref ref-type="table-fn" rid="table-fn1-2045125312469982">*</xref></td>
<td/>
<td/>
<td/>
<td/>
<td>Sinus bradycardia</td>
<td>1<xref ref-type="table-fn" rid="table-fn1-2045125312469982">*</xref></td>
</tr>
<tr>
<td>16[<xref ref-type="bibr" rid="bibr64-2045125312469982">Sekine <italic>et al</italic>. 2007</xref>]</td>
<td>591</td>
<td>240</td>
<td>No</td>
<td>59</td>
<td>M</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>0</td>
</tr>
<tr>
<td>17[<xref ref-type="bibr" rid="bibr79-2045125312469982">Wong <italic>et al</italic>. 2007</xref>]</td>
<td>516</td>
<td>375</td>
<td>No</td>
<td>22</td>
<td>M</td>
<td/>
<td/>
<td/>
<td/>
<td>Sinus bradycardia, cocaine</td>
<td>2</td>
</tr>
<tr>
<td>18[<xref ref-type="bibr" rid="bibr23-2045125312469982">Falconer <italic>et al</italic>. 2007</xref>]</td>
<td>555</td>
<td>105</td>
<td>Yes</td>
<td>34</td>
<td>M</td>
<td/>
<td/>
<td>Protease Inhibitors: Atazanavir (CYP3A4) and Ritonavir (CYP3A4, CYP2B6)</td>
<td>Yes</td>
<td>Sinus bradycardia</td>
<td>4</td>
</tr>
<tr>
<td>19[<xref ref-type="bibr" rid="bibr30-2045125312469982">Iskandar <italic>et al</italic>. 2007</xref>]</td>
<td>605</td>
<td>160</td>
<td>Yes</td>
<td>43</td>
<td>F</td>
<td>Yes</td>
<td/>
<td/>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>20[<xref ref-type="bibr" rid="bibr1-2045125312469982">Abramson <italic>et al</italic>. 2008</xref>]</td>
<td>600</td>
<td>230</td>
<td>Yes</td>
<td>47</td>
<td>F</td>
<td/>
<td/>
<td>Amiodarone (QTP)</td>
<td>Yes</td>
<td/>
<td>3</td>
</tr>
<tr>
<td>21[<xref ref-type="bibr" rid="bibr53-2045125312469982">Pimentel <italic>et al</italic>. 2008</xref>]</td>
<td>577</td>
<td>135</td>
<td>Yes</td>
<td>40</td>
<td>F</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>1</td>
</tr>
<tr>
<td>22[<xref ref-type="bibr" rid="bibr22-2045125312469982">Esses <italic>et al</italic>. 2008</xref>]</td>
<td>580</td>
<td>100</td>
<td>Yes</td>
<td>56</td>
<td>M</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>0</td>
</tr>
<tr>
<td>23[<xref ref-type="bibr" rid="bibr54-2045125312469982">Prosser <italic>et al</italic>. 2008</xref>]</td>
<td>690</td>
<td>125</td>
<td>Yes</td>
<td>57</td>
<td>M</td>
<td>Yes</td>
<td/>
<td>Voriconazole (CYP3A4, QTP), Cannabinoids (CYP3A4)</td>
<td/>
<td>Sinus bradycardia, cocaine</td>
<td>6</td>
</tr>
<tr>
<td>24[<xref ref-type="bibr" rid="bibr50-2045125312469982">Nair <italic>et al</italic>. 2008</xref>]</td>
<td>538</td>
<td>120</td>
<td>Yes</td>
<td>56</td>
<td>M</td>
<td/>
<td>↓K</td>
<td>Ciprofloxacin (CYP3A4, QTP)</td>
<td>Yes</td>
<td/>
<td>4</td>
</tr>
<tr>
<td>25[<xref ref-type="bibr" rid="bibr58-2045125312469982">Reinhold <italic>et al</italic>. 2009</xref>]</td>
<td>600</td>
<td>125</td>
<td>Yes</td>
<td>57</td>
<td>M</td>
<td>Yes</td>
<td/>
<td>Voriconazole(CYP3A4, QTP), Cannabinoids (CYP3A4), Amiodarone (QTP)</td>
<td/>
<td>Sinus bradycardia, cocaine</td>
<td>7</td>
</tr>
<tr>
<td>26[<xref ref-type="bibr" rid="bibr51-2045125312469982">Noorzurani <italic>et al</italic>. 2009</xref>]</td>
<td>520</td>
<td>120</td>
<td>Yes</td>
<td>44</td>
<td>F</td>
<td/>
<td/>
<td>Itraconazole (CYP3A4)</td>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>27[<xref ref-type="bibr" rid="bibr55-2045125312469982">Puri <italic>et al</italic>. 2009</xref>]</td>
<td>540</td>
<td>70</td>
<td>Yes</td>
<td>36</td>
<td>F</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>1</td>
</tr>
<tr>
<td>28[<xref ref-type="bibr" rid="bibr31-2045125312469982">John <italic>et al</italic>. 2010</xref>]</td>
<td>550</td>
<td>40</td>
<td>Yes</td>
<td>50</td>
<td>M</td>
<td/>
<td/>
<td>Cotrimoxazole (CYP3A4, QTP), Protease Inhibitor: Atazanavir (CYP3A4)</td>
<td/>
<td/>
<td>3</td>
</tr>
<tr>
<td>29[<xref ref-type="bibr" rid="bibr17-2045125312469982">De Jong <italic>et al</italic>. 2011</xref>]</td>
<td>600</td>
<td>Unknown</td>
<td>Yes</td>
<td>52</td>
<td>M</td>
<td/>
<td/>
<td/>
<td>Yes</td>
<td>Cocaine</td>
<td>2</td>
</tr>
<tr>
<td>30[<xref ref-type="bibr" rid="bibr52-2045125312469982">Nordt <italic>et al</italic>. 2011</xref>]</td>
<td>569</td>
<td>Unknown</td>
<td>Yes</td>
<td>55</td>
<td>M</td>
<td/>
<td/>
<td>Amiodarone (QTP), <break/>Doxepin (QTP)</td>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>31[<xref ref-type="bibr" rid="bibr67-2045125312469982">Thanavaro <italic>et al</italic>. 2011</xref>]</td>
<td>626</td>
<td>110</td>
<td>Yes</td>
<td>61</td>
<td>M</td>
<td/>
<td>↓K<break/>↓Mg</td>
<td/>
<td/>
<td/>
<td>2</td>
</tr>
<tr>
<td>32[<xref ref-type="bibr" rid="bibr12-2045125312469982">Calver <italic>et al</italic>. 2012</xref>]</td>
<td>480</td>
<td>120</td>
<td>No</td>
<td>27</td>
<td>M</td>
<td/>
<td/>
<td>Cannabinoids (CYP3A4)</td>
<td/>
<td>Sinus bradycardia</td>
<td>2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2045125312469982">
<label>*</label>
<p>Female sex not a risk as patient was an infant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Among the 21 subjects—nine men and 12 women—(Table 1—patients 1, 6, 7, 9-14, 18-28 and 31 cases are printed in red) (1) developing <italic>TdP</italic>, (2) having QTc interval measurements in close proximity to the time they developed this arrhythmia and (3) having daily methadone doses recorded at the time of <italic>TdP</italic>, there were insignificant correlations between QTc interval and methadone dose using both parametric and nonparametric statistics (Pearson <italic>r</italic> = −0.263, <italic>p</italic> = 0.249, Kendall’s tau_b −0.39, <italic>p</italic> = 0.808, Spearman’s rho = 0.005, <italic>p</italic> = 0.982). When we assessed the correlation between methadone dose and total risk factors (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>), we again found an insignificant inverse relationship using both parametric and nonparametric statistics (Pearson <italic>r</italic> = −0.084, <italic>p</italic> = 0.663, Kendall’s tau_b −0.46, <italic>p</italic> = 0.744, Spearman’s rho = −0.071, <italic>p</italic> = 0.714). (Even though all subjects received methadone and this drug constitutes a risk factor for QTc interval prolongation, we did not include methadone in our calculations of the relationship between methadone dose and total risk factors.) This is not a case control study and all statistical assertions made above have significant limitations. We discuss these limitations further when we compare our findings with those from the literature in the discussion.</p>
<p>Major risk factors (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) for QTc interval prolongation and <italic>TdP</italic> among the 31 adult methadone users in our sample included (1) female sex (<italic>n</italic>=12), (2) heart disease (<italic>n</italic>=11), (3) electrolyte imbalance [hypokalemia (<italic>n</italic>=7) and hypomagnesemia (<italic>n</italic>=4)], (4) metabolic (CYP) drug interactions (<italic>n</italic>=19), (5) concurrent use of medications associated with QTc interval prolongation (<italic>n</italic>=14), (6) hepatic impairment (<italic>n</italic>=6), (7) and other risk factors: sinus bradycardia (<italic>n</italic>=8) and cocaine (<italic>n</italic>=6). Twenty-four of 31 adult patients (77.4%) had multiple risk factors besides methadone. This observation may add importantly to understanding our data.</p>
</sec>
<sec id="section7-2045125312469982" sec-type="discussion">
<title>Discussion</title>
<p>Our two main findings (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) were (1) using both parametric and nonparametric statistics, no obvious relationship between methadone dose and QTc interval prolongation in patients taking methadone and developing <italic>TdP</italic> and (2) the common finding of multiple risk factors for <italic>TdP</italic> present in patients taking methadone without any obvious correlation between methadone dose and number of risk factors. The risk factors we identified (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) were similar to those previously reported among methadone patients[<xref ref-type="bibr" rid="bibr38-2045125312469982">Krantz <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. 2010</xref>] and patients taking noncardiac drugs [<xref ref-type="bibr" rid="bibr75-2045125312469982">Viskin <italic>et al</italic>. 2003</xref>]. In non-methadone psychotropic drug-induced/associated <italic>TdP</italic>, two women appear for every man. Among the elderly with this problem, women may represent up to 90% of the cases [<xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>]. However, adult men appeared more commonly than women in our study (19 <italic>versus</italic> 12).</p>
<sec id="section8-2045125312469982">
<title>Predicting methadone-induced QTc interval prolongation and TdP</title>
<p>Investigators have proposed large subject sizes to predict methadone-induced QTc interval prolongation and associated <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr16-2045125312469982">Cruciani, 2008</xref>], but such recommendations assume that parametric statistics apply in this setting and this appears to be a false assumption [<xref ref-type="bibr" rid="bibr66-2045125312469982">Taleb, 2010</xref>]. Methadone exposure may link to increased sudden cardiac death (SCD) in the community even among those with therapeutic levels of methadone [<xref ref-type="bibr" rid="bibr14-2045125312469982">Chugh <italic>et al</italic>. 2008</xref>]. QTc interval prolongation, when it reaches 500 msec or more, predicts a population vulnerable to polymorphic ventricular tachycardia and its better known subtype <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>, <xref ref-type="bibr" rid="bibr71-2045125312469982">Vieweg <italic>et al</italic>. 2011</xref>]. However, the rarity of these arrhythmias precludes using QTc interval prolongation alone to quantitate the risk of drug-induced SCD.</p>
<p><xref ref-type="bibr" rid="bibr4-2045125312469982">Anchersen <italic>et al</italic>. [2009]</xref> reported the prevalence of QTc interval prolongation among subjects in opioid maintenance treatment and the potential mortality associated with QTc interval prolongation in the Norwegian opioid maintenance treatment program. Among the 173 patients receiving methadone, 4.6% had QTc interval &gt;500 msec (all taking methadone ≥120 mg), 15% had QTc interval &gt;470 msec and 28.9% had QTc interval &gt;450 msec. The authors found a positive dose-dependent relationship between methadone dose and QTc interval lengthening (Pearson <italic>r</italic>=0.37, <italic>p</italic>&lt;0.01; multiple regression analysis B=0.37, <italic>p</italic>&lt;0.01). A case control study was not performed. During the first month of methadone maintenance treatment, two deaths occurred among 3850 initiations of methadone maintenance. One patient died from intracranial bleeding and one cause of death was unknown. <xref ref-type="bibr" rid="bibr4-2045125312469982">Anchersen <italic>et al</italic>. [2009]</xref> concluded that death due to methadone during the first month of treatment was low and did not exceed 0.06 per 100 patient-years. The authors did not report the presence or absence of risk factors associated with <italic>TdP</italic> and attendant QTc interval prolongation in this paper but did look at their patients with QTc interval &gt;500 msec in a second paper [<xref ref-type="bibr" rid="bibr5-2045125312469982">Anchersen <italic>et al</italic>. 2010</xref>].</p>
<p><xref ref-type="bibr" rid="bibr5-2045125312469982">Anchersen <italic>et al</italic>. [2010]</xref> provided a detailed review of their earlier subjects with QTc interval &gt;500 msec with a particular focus on risk factors. Assessment included a detailed medical and cardiac history, genetic testing for the five most common long QT syndrome mutations, cardiac exercise testing and 24-hour Holter monitor records. The authors assessed seven subjects and found that two were heterozygous long QT syndrome mutation carriers who had both experienced cardiac complaints before and during opioid maintenance treatment. The authors detected no additional risk factor among these seven patients. In six subjects, QTc intervals fluctuated widely during 24-hour Holter monitor recording and exercise testing [<xref ref-type="bibr" rid="bibr5-2045125312469982">Anchersen <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section9-2045125312469982">
<title>Methadone-associated QTc interval prolongation</title>
<p>More than 80% of patients receiving long-term methadone maintenance therapy may have QTc interval prolongation compared with reference values for patients of the same age and sex and there may be no correlation between QTc interval measurement and methadone dose [<xref ref-type="bibr" rid="bibr47-2045125312469982">Maremmani <italic>et al</italic>. 2005</xref>]. However, others have reported a positive relationship between methadone dose and QTc interval duration [<xref ref-type="bibr" rid="bibr35-2045125312469982">Kornick <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr37-2045125312469982">Krantz <italic>et al</italic>. 2003</xref>]. Among our 21 cases of methadone-associated <italic>TdP</italic>, we failed to identify any relationship between QTc interval prolongation and methadone dose. Perhaps, multiple risk factors present may explain this finding.</p>
<p>A paper recently published by <xref ref-type="bibr" rid="bibr61-2045125312469982">Roy <italic>et al</italic>. [2012]</xref> studied 180 subjects (69.1% men) in a methadone maintenance therapy program. Mean QTc interval was 420.9 ± 21.1 msec and the mean daily methadone dose was 80.4 ± 27.7 mg. There was no significant correlation between these two measurements (<italic>p</italic> = 0.33) with 8.8% of patients demonstrating QTc interval prolongation (8.3% men and 0.5% women).</p>
<p>In contrast to the uneven findings of the relationship between QTc interval prolongation among <italic>TdP</italic> patients and methadone dose in our and other studies, <xref ref-type="bibr" rid="bibr49-2045125312469982">Miceli <italic>et al</italic>. [2010]</xref> found a significant positive correlation between therapeutic doses of both ziprasidone and haloperidol and QTc interval measurements in 59-medically-healthy adults with either schizophrenia or schizoaffective disorder in a well-controlled study. No patient developed QTc interval of ≥450 msec. Several factors distinguished the Miceli <italic>et al</italic>. paper from the methadone papers: (1) QTc interval measurements related positively to antipsychotic drug dose (i.e., the higher the drug dose, the greater the QTc interval), (2) neither ziprasidone nor haloperidol administrations were associated with QTc interval prolongation or <italic>TdP</italic> and (3) no risk factors for QTc interval prolongation were present such as drugs that inhibited antipsychotic drug metabolism or linked to QTc interval prolongation itself.</p>
</sec>
</sec>
<sec id="section10-2045125312469982">
<title>Case series in the literature</title>
<p><xref ref-type="bibr" rid="bibr38-2045125312469982">Krantz <italic>et al</italic>. [2002]</xref> reported 17 patients (mean QTc interval 615±77 msec on presentation) who developed <italic>TdP</italic> while taking methadone (mean daily dose 397±283 mg). Their data were tabulated but did not contain the breadth and depth of information found in a case report format. The authors concluded that very-high-dose methadone might cause <italic>TdP</italic>. The next year, <xref ref-type="bibr" rid="bibr37-2045125312469982">Krantz <italic>et al</italic>. [2003]</xref> reported the dose-related effects of methadone on QTc interval prolongation in their 17 patients with methadone-associated <italic>TdP</italic>. Only the daily dose of methadone predicted the QTc interval (<italic>r</italic>=+0.51, <italic>p</italic>=0.03). They did not conduct a case control study.</p>
<p><xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. [2010]</xref> reported a retrospective case series of 12 consecutive patients (mean daily methadone dose 135 mg) hospitalized with methadone-induced QTc interval prolongation and <italic>TdP</italic> during the study period July 2007 to April 2009. Their hospital was the only referral source for 6500 methadone maintenance patients. Thus monthly (21 months), 12/21 (0.57) of 6500 (0.57/6500=0.0000879) or 8.8×10<sup>−5</sup> patients experienced changes sufficient to produce <italic>TdP</italic> and live long enough to be hospitalized. (Daily risk would be 8.8/30×10<sup>−5</sup> or 2.9×10<sup>−6</sup> patients or about 3 episodes of <italic>TdP</italic> daily per 1 million methadone maintenance treatment patients.) The authors did not say how many of these 6500 patients experienced SCD outside the hospital.</p>
<sec id="section11-2045125312469982">
<title>Sex differences in methadone exposure and QTc interval prolongation</title>
<p>We found, as did others [<xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. 2010</xref>], that men are more commonly involved in cases of methadone-associated QTc interval prolongation and <italic>TdP</italic> than women. This contrasts to many observations that women are more commonly involved in non-cardiac drug-associated QTc interval prolongation and <italic>TdP</italic> than are men [<xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr71-2045125312469982">Vieweg <italic>et al</italic>. 2011</xref>]. With the onset of puberty, the QT interval shortens for men by about 20 msec (androgen effect) compared with women.</p>
<p><xref ref-type="bibr" rid="bibr13-2045125312469982">Chang <italic>et al</italic>. [2011]</xref> performed a cross-sectional analysis of low-dose methadone and sex effects in 283 heroin-dependent patients (229 men and 54 women) undergoing QTc interval measurement 59 days (interquartile range: 36 to 288 days) after starting methadone treatment. To assess methadone over time, a 150-patient subset (126 men and 24 women) underwent QTc interval assessment before and 37 days (interquartile range 32-44 days) after starting methadone therapy. Methadone dose-QTc interval correlation was significant for men (<italic>r</italic>=0.210, <italic>p</italic>=0.0014) but not for women (<italic>r</italic>=0.164, <italic>p</italic>=0.2363). Over six-months, 60.7% of patients developed an increase in their QTc interval compared with baseline measurements. QTc interval significantly increased in men (from 418.5 to 426.9 msec, <italic>p</italic>&lt;0.0001) but not in women (from 437.7 to 441.1 msec, <italic>p</italic>=0.468). The authors concluded that (1) low-dose methadone treatment demonstrates dose-dependent QTc interval prolongation and links to significant QTc interval lengthening within six months of starting methadone treatment and (2) men are more susceptible than women are to low-dose methadone-associated QTc interval prolongation.</p>
<p><xref ref-type="bibr" rid="bibr48-2045125312469982">Martell <italic>et al</italic>. [2005]</xref> prospectively assessed methadone (20-200 mg/day) effects on QTc intervals in 160 patients possessing varying numbers of risk factors for QTc interval prolongation. Women had significantly longer QTc intervals than men at baseline did. At six-month follow-up, however, factors associated with greater QTc interval prolongation included male sex and methadone dose at which time 13% of men and 11% of women demonstrated QTc interval prolongation. At 12-month follow-up, methadone dose marginally linked to greater QTc interval prolongation at which time 20% of men and 2% of women showed QTc interval prolongation. No cases of <italic>TdP</italic> appeared in this study. Their work [<xref ref-type="bibr" rid="bibr48-2045125312469982">Martell <italic>et al</italic>. 2005</xref>] coupled with others [<xref ref-type="bibr" rid="bibr47-2045125312469982">Maremmani <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr65-2045125312469982">Sticherling <italic>et al</italic>. 2005</xref>] suggest that more than 80% of patients in methadone maintenance programs have some degree of QTc interval prolongation as discussed earlier.</p>
<p>Men are more likely to abuse drugs than women are. <xref ref-type="bibr" rid="bibr81-2045125312469982">Zickler [2000]</xref> traces this finding to opportunities to use drugs of abuse. This observation applies to heroin abusers and, therefore, subsequent abusers requiring methadone maintenance therapy. Among our adults, 19 of 32 case reports (59.4%) involved men (<xref ref-type="table" rid="table1-2045125312469982">Tables 1</xref>). In the <xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. [2010]</xref> series, 9 of 12 (75%) cases were men. In the <xref ref-type="bibr" rid="bibr13-2045125312469982">Chang <italic>et al</italic>. [2011]</xref> series, 229 of 283 (80.9%) subjects were men. If methadone was the main risk factor for <italic>TdP</italic> and uniformly led to QTc interval prolongation among women and men in the cases under discussion, we would expect this drug to maintain the 2:1 F:M ratio found in non-methadone psychotropic drug-induced cases of QTc interval prolongation and <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr71-2045125312469982">Vieweg <italic>et al</italic>. 2011</xref>]. We believe the preponderance of male methadone cases is because men are much more likely than women to require methadone treatment for a variety of reasons and this findings overrides greater female vulnerability to drug-induced QTc interval prolongation and <italic>TdP</italic> [<xref ref-type="bibr" rid="bibr45-2045125312469982">Makkar <italic>et al</italic>. 1993</xref>].</p>
</sec>
<sec id="section12-2045125312469982">
<title>Risk factors for QTc interval prolongation and TdP</title>
<p>We have reviewed risk factors for QTc interval prolongation and <italic>TdP</italic> previously [<xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>]. Electrolyte disturbances [particularly hypokalemia (commonly diuretic-induced) and hypomagnesemia (commonly found during hospitalization in general and intensive care units [<xref ref-type="bibr" rid="bibr2-2045125312469982">Agus, 1999</xref>]) and among alcoholics [<xref ref-type="bibr" rid="bibr9-2045125312469982">Backmund <italic>et al</italic>. 2003]</xref>] are among these risk factors [<xref ref-type="bibr" rid="bibr8-2045125312469982">Arbel <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. 2010</xref>].</p>
<p><xref ref-type="bibr" rid="bibr10-2045125312469982">Bednar <italic>et al</italic>. [2001]</xref> in their Table 2 identified 16 factors prolonging the QTc interval. Those risk factors included (1) congenital, (2) increasing age, (3) female sex, (4) meals, (5) sleep, (6) drugs, (7) obesity/weight gain, (8) liquid protein diet, (9) alcoholism, (10) electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia), (11) hypoglycemia/diabetes mellitus, (12) myocardial ischemia and infarction, cardiomyopathy, (13) hypertension, (14) hypothyroidism/pituitary insufficiency, (15) central nervous system insult: stroke, subarachnoid hemorrhage, trauma, infection, tumor and (16) cirrhosis.</p>
<p><xref ref-type="bibr" rid="bibr75-2045125312469982">Viskin <italic>et al</italic>. [2003]</xref> in their review (Figure 3 derived from 229 published cases) of the long QT syndrome caused by noncardiac drugs identified seven major risk factors in order of greatest to least as follows: (1) female sex, (2) heart disease, (3) hypokalemia, (4) toxic drug levels, (5) drug interactions involving the QT interval, (6) metabolic drug interactions and (7) familial history of long QT syndrome. The authors found that 96% of their study subjects had one or more risk factors, 72% had two or more risk factors and 39.5% had three or more risk factors. In our <xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>, we slightly modified this list to include (1) female sex, (2) heart disease, (3) hypokalemia/hypomagnesemia, (4) drug interactions involving the QT interval and metabolic drug interactions, (5) hepatic impairment and (6) others including sinus bradycardia and cocaine.</p>
</sec>
<sec id="section13-2045125312469982">
<title>High-dose methadone (120 mg/day and above)</title>
<p>The United Kingdom methadone treatment guidelines [<xref ref-type="bibr" rid="bibr19-2045125312469982">Department of Health (England) and the Devolved Administrations, 2007</xref>] recommend obtaining an EKG in persons taking greater than 100 mg of methadone per day. Anchersen et al found an association with dosages ≥120 mg and QTc interval &gt; 500 msec [<xref ref-type="bibr" rid="bibr4-2045125312469982">Anchersen <italic>et al</italic>. 2009</xref>]. Twenty-three of our 31 adults (74.2%) were exposed to daily methadone doses of 120 mg or greater (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>). In the <xref ref-type="bibr" rid="bibr28-2045125312469982">Hanon <italic>et al</italic>. [2010]</xref> series, seven of 12 subjects (daily dose range 35 to 250 mg) received daily doses of methadone 140 mg or greater. In contrast to daily methadone doses of up to 700 mg daily (our <xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>), these patients were exposed to no more than 250 mg of methadone/day. In our sample, seven cases (25.8%) experienced QTc interval prolongation at doses less than 120 mg per day, with the lowest dosage reported being only 40 mg of methadone. Even though a methadone dose effect on QTc interval lengthening may appear [<xref ref-type="bibr" rid="bibr37-2045125312469982">Krantz <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr13-2045125312469982">Chang <italic>et al</italic>. 2011</xref>], its clinical utility is highly questionable [<xref ref-type="bibr" rid="bibr16-2045125312469982">Cruciani, 2008</xref>].</p>
</sec>
<sec id="section14-2045125312469982">
<title>Drug interactions</title>
<sec id="section15-2045125312469982">
<title>Co-administration of methadone metabolic inhibitors</title>
<p>Methadone is metabolized hepatically by N-demethylation via cytochrome P-450 isoforms, primarily CYP3A4, CYP2B6, CYP2C19 and to a lesser degree by CYP2C9 and CYP2D6. Coadministration of methadone with enzyme inducers may cause more rapid methadone metabolism potentially decreasing methadone effects. Coadministration of CYP inhibitors may slow metabolism thereby potentiating methadone’s effects. When coadministering methadone with drugs known to both induce and inhibit CYP enzymes, its pharmacokinetics may change unpredictably. Antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir and lopinavir + ritonavir combination will inhibit some CYPs. These drugs may also reduce methadone plasma levels due to CYP induction. Therefore, always evaluate drugs concomitantly administered with methadone for their interaction potential and evaluate individual response to drug therapy before adjusting the dose [<xref ref-type="bibr" rid="bibr6-2045125312469982">Anderson <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr60-2045125312469982">Roxane Laboratories, 2003</xref>].</p>
<p>Although methadone is primarily metabolized by CYP3A4, CPY2B6 and CYP2C19 are also important in methadone metabolism. CYP3A4 metabolic inhibitors administered to our 31 adult patients (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) included fluoxetine (<italic>n</italic>=2), cannabinoids (<italic>n</italic>=4), clarithromycin (<italic>n</italic>=1), cotrimoxazole (sulfamethoxazole/trimethoprim) (<italic>n</italic>=3), fluvoxamine (<italic>n</italic>=1), protease inhibitors (<italic>n</italic>=3), ciprofloxacin (<italic>n</italic>=1), itraconazole (<italic>n</italic>=1) and voriconazole (<italic>n</italic>=2). CYP2B6 metabolic inhibitors administered to our 31 adult patients (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) included sertraline and ritonavir, a protease inhibitor. CYP2C19 inhibitors included fluoxetine and sertraline.</p>
<p>Concomitant administration of drugs that may prolong the QTc interval may lead to QTc interval prolongation and <italic>TdP</italic>. Medications with the potential to prolong the QTc interval in our 31 adult patients (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>) included amiodarone (<italic>n</italic>=3), ciprofloxacin (<italic>n</italic>=1), cotrimoxazole (<italic>n</italic>=3), doxepin (<italic>n</italic>=1), foscarnet (<italic>n</italic>=1), fluoxetine (<italic>n</italic>=2) and voriconazole (<italic>n</italic>=2).</p>
</sec>
</sec>
<sec id="section16-2045125312469982">
<title>Multiple risk factors and TdP among subjects exposed to methadone</title>
<p>Among the 27 case reports involving <italic>TdP</italic> (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>), 22 (81.5%) had multiple risk factors for this potentially fatal cardiac arrhythmia—that is, risk factors in addition to exposure to methadone. This characteristic has been reported by others and our group previously [<xref ref-type="bibr" rid="bibr80-2045125312469982">Zeltser <italic>et al</italic>. 2003</xref>; <xref ref-type="bibr" rid="bibr74-2045125312469982">Vieweg <italic>et al</italic>. 2009</xref>].</p>
<p><xref ref-type="bibr" rid="bibr80-2045125312469982">Zeltser <italic>et al</italic>. [2003]</xref> reviewed risk factors for <italic>TdP</italic> among subjects taking non-cardiac drugs. They asserted that these risk factors (female sex, heart disease, electrolyte imbalances, excessive dosing, drugs interactions and family history of long QT syndrome) are easily identifiable from the medical history and/or clinical evaluation. In their review, they identified 249 subjects with <italic>TdP</italic> associated with non-cardiac drugs. Female sex was the most common risk factor (71%), almost all of their subjects had at least one risk factor and 71% had two or more risk factors. The authors concluded clinicians planning to prescribe non-cardiac drugs associated with <italic>TdP</italic> could easily identify risk factors for <italic>TdP</italic> before prescribing the culprit drug. Unfortunately, Zeltser <italic>et al</italic>. do not report how often the culprit drug is prescribed for patients with risk factors for <italic>TdP</italic> and yet it does not occur—hence, a major problem in estimating risk.</p>
<p>Included in risk factors for <italic>TdP</italic> may be acute structural cardiac changes in certain settings. <xref ref-type="bibr" rid="bibr15-2045125312469982">Crotti <italic>et al</italic>. [2012]</xref> recently described <italic>TdP</italic> following acute myocardial infarction (AMI) in a genetic substrate predisposed to a time-limited development of life-threatening ventricular tachyarrhythmias. The authors studied 13 patients who developed <italic>TdP</italic> during the subacute phase of AMI. The comparison group constituted 133 ethnically-matched controls with uncomplicated AMI. They screened for long QT syndrome genes and the <italic>KCNH2</italic>-K897T polymorphism. They found that two of the 13 patients presenting with QTc interval prolongation and <italic>TdP</italic> carried long QT syndrome mutations (<italic>KCHN2</italic>-R744X and <italic>SCN5A</italic>-E446K). Nine of the remaining 11 patients carried the <italic>KCNH2</italic>-K897T polymorphism as did 35% of controls (<italic>p</italic>=0.0035). The authors concluded that AMI patients carrying the <italic>KCNH2</italic>-K897T polymorphism are eight times more likely to develop <italic>TdP</italic> than controls. Administration of methadone or any other drug associated with QTc interval prolongation in this setting likely would further increase the risk of developing <italic>TdP</italic>.</p>
<sec id="section17-2045125312469982">
<title>Scalable randomness and predicting drug-induced TdP</title>
<p><xref ref-type="bibr" rid="bibr56-2045125312469982">Raschi <italic>et al</italic>. [2009]</xref> recently reviewed models for predicting hERG liability (I<sub>Kr</sub> blockade) and QT interval prolongation. They reported that 40 to 70% of new model entries considered as potential therapeutic drugs are abandoned early in development because they test positive for hERG blocking liability. However, lack of hERG blocking liability does not preclude a drug from linking to QTc interval prolongation and <italic>TdP</italic>.</p>
<p>Our study suggests that QTc interval prolongation in the setting of <italic>TdP</italic> is not linked to methadone dose, is not predictable at present and may not be Gaussian in distribution. <xref ref-type="bibr" rid="bibr56-2045125312469982">Raschi <italic>et al</italic>. [2009]</xref> identified many risk factors underlying drug-induced <italic>TdP</italic> onset including organ impairment, drug interactions, electrolyte imbalance and genetic mutations leading to reduced repolarization reserve. Additional mechanisms and mathematical models are probably operative—especially Chaos theory [<xref ref-type="bibr" rid="bibr26-2045125312469982">Gleick, 1987</xref>]. Minute differences in the initial conditions (genetic makeup, medication profile, electrolytes, structural abnormalities, etc.) tend to evolve into extraordinarily different outcomes (slight QT prolongation vs <italic>TdP</italic>) when exposed to methadone. We believe that any useful effort to predict methadone-associated <italic>TdP</italic> and attendant QTc interval prolongation must better understand the role of the above-identified risk factors in <italic>TdP</italic>.</p>
<p><xref ref-type="bibr" rid="bibr66-2045125312469982">Taleb [2010]</xref> discussed the concept of scalable randomness citing an example as follows. Expect a project to be finished in 79 days. If not completed, anticipate another 25 days. However if the project remains unfinished by the 90<sup>th</sup> day, it should take another 58 days to complete. On the 100<sup>th</sup> day, it should have 89 days to completion and on the 119<sup>th</sup> day, it will have another 149 days to go. If not finished by the 600<sup>th</sup> day, an additional 1590 days will be necessary. It follows that added and unanticipated complexity drives each delay. Similarly, added and unanticipated risk factors appear in patients destined to develop <italic>TdP</italic> independent of the original drug prescribed. If so, the QTc interval-prolonging drug may be a prerequisite but not sufficient without additional risk factors to best explain drug-associated <italic>TdP</italic>. It follows that multiple risk factors including the drug itself add complexity and uncertainty sufficient to negate parametric statistics as an approach to studying this problem.</p>
</sec>
</sec>
<sec id="section18-2045125312469982">
<title>What to do with our data and similar data from the literature?</title>
<p>Heroin dependency was the most common indication for methadone administration among our 31 adult subjects (<xref ref-type="table" rid="table1-2045125312469982">Table 1</xref>). Twenty-four of them (77.4%) received methadone to treat heroin dependence and seven (22.6%) received methadone for pain relief. These are the two most common indications for methadone administration and simply tell us that any patient taking methadone may be at risk for <italic>TdP</italic>. The rarity of <italic>TdP</italic> among methadone users precludes knowing how many methadone users do not develop <italic>TdP</italic> and what factors separate these two groups. Therefore, we must study the published data on the subject via the case report format to learn as much as possible about <italic>TdP</italic>. Unfortunately, both the FDA and drug manufacturers tend not to make case report material available compounding the effort to better understand the relationship between psychotropic drugs and <italic>TdP</italic> in general and the relationship between methadone and <italic>TdP</italic> in particular.</p>
</sec>
</sec>
<sec id="section19-2045125312469982">
<title>Study limitations</title>
<p>The most obvious study limitations are data derived from case reports and the inability to provide risk estimates. Narrative medicine in the form of case reports is inherently selective and may or may not provide representative data of clinical relevance to the medical issues discussed. Studying extreme outliers (Black Swans [<xref ref-type="bibr" rid="bibr66-2045125312469982">Taleb, 2010</xref>]) in an effort to better understand <italic>TdP</italic> may be inherently impossible.</p>
</sec>
<sec id="section20-2045125312469982" sec-type="conclusions">
<title>Conclusions</title>
<p>At present, clinicians and oversight agencies such as the FDA must study case report material for guidance despite its limitations and hazards. We describe risk factors for methadone-associated QTc interval prolongation and <italic>TdP</italic> based on case reports. We believe both drug manufactures and the FDA would better protect our patients and better inform clinicians if they more readily reported drug-induced outliers using a case report format with a particular emphasis on multiple risk factors.</p>
</sec>
</body>
<back>
<ref-list>
<title>Reference List</title>
<ref id="bibr1-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abramson</surname><given-names>D.W.</given-names></name>
<name><surname>Quinn</surname><given-names>D.K.</given-names></name>
<name><surname>Stern</surname><given-names>T.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Methadone-associated QTc prolongation: a case report and review of the literature</article-title>. <source>Prim Care Comp J Clin Psychiatry</source> <volume>10</volume>: <fpage>470</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr2-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agus</surname><given-names>Z.S.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Hypomagnesemia</article-title>. <source>J Am Soc Nephrol</source> <volume>10</volume>: <fpage>1616</fpage>–<lpage>1622</lpage>.</citation>
</ref>
<ref id="bibr3-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Almehmi</surname><given-names>A.</given-names></name>
<name><surname>Malas</surname><given-names>A.M.</given-names></name>
<name><surname>Yousufuddin</surname><given-names>M.</given-names></name>
<name><surname>Rosencrance</surname><given-names>J.G.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Methadone-induced torsade de pointes in a patient with normal baseline QT interval</article-title>. <source>West Virginia M J</source> <volume>100</volume>: <fpage>147</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr4-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anchersen</surname><given-names>K.</given-names></name>
<name><surname>Clausen</surname><given-names>T.</given-names></name>
<name><surname>Gossop</surname><given-names>M.</given-names></name>
<name><surname>Hansteen</surname><given-names>V.</given-names></name>
<name><surname>Waal</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study</article-title>. <source>Addiction</source> <volume>104</volume>: <fpage>993</fpage>–<lpage>999</lpage>.</citation>
</ref>
<ref id="bibr5-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anchersen</surname><given-names>K.</given-names></name>
<name><surname>Hansteen</surname><given-names>V.</given-names></name>
<name><surname>Gossop</surname><given-names>M.</given-names></name>
<name><surname>Clausen</surname><given-names>T.</given-names></name>
<name><surname>Waal</surname><given-names>H.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor</article-title>. <source>Drug Alcohol Depend</source> <volume>112</volume>: <fpage>216</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr6-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>I.B.</given-names></name>
<name><surname>Kearney</surname><given-names>T.E.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Use of methadone</article-title>. <source>Western J Med</source> <volume>172</volume>: <fpage>43</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr7-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ansermot</surname><given-names>N.</given-names></name>
<name><surname>Albayrak</surname><given-names>O.</given-names></name>
<name><surname>Schlapfer</surname><given-names>J.</given-names></name>
<name><surname>Crettol</surname><given-names>S.</given-names></name>
<name><surname>Croquette-Krokar</surname><given-names>M.</given-names></name>
<name><surname>Bourquin</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval</article-title>. <source>Arch Intern Med</source> <volume>170</volume>: <fpage>529</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr8-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arbel</surname><given-names>Y.</given-names></name>
<name><surname>Swartzon</surname><given-names>M.</given-names></name>
<name><surname>Justo</surname><given-names>D.</given-names></name>
</person-group> (<year>2007</year>) <article-title>QT Prolongation and torsades de pointes in patients previously treated with anthracyclines</article-title>. <source>Anti-Cancer Drugs</source> <volume>18</volume>: <fpage>493</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr9-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Backmund</surname><given-names>M.</given-names></name>
<name><surname>Schutz</surname><given-names>C.G.</given-names></name>
<name><surname>Meyer</surname><given-names>K.</given-names></name>
<name><surname>Eichenlaub</surname><given-names>D.</given-names></name>
<name><surname>Soyka</surname><given-names>M.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients–frequency and correlates of use</article-title>. <source>Eur Addiction Res</source> <volume>9</volume>: <fpage>45</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr10-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bednar</surname><given-names>M.M.</given-names></name>
<name><surname>Harrigan</surname><given-names>E.P.</given-names></name>
<name><surname>Anziano</surname><given-names>R.J.</given-names></name>
<name><surname>Camm</surname><given-names>A.J.</given-names></name>
<name><surname>Ruskin</surname><given-names>J.N.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The QT interval</article-title>. <source>Prog Cardiovasc Dis</source> <volume>43</volume> (<issue>5 Suppl 1</issue>): <fpage>1</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr11-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brachmann</surname><given-names>J.</given-names></name>
<name><surname>Scherlag</surname><given-names>B.J.</given-names></name>
<name><surname>Rosenshtraukh</surname><given-names>L.V.</given-names></name>
<name><surname>Lazzara</surname><given-names>R.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia</article-title>. <source>Circulation</source> <volume>68</volume>: <fpage>846</fpage>–<lpage>856</lpage>.</citation>
</ref>
<ref id="bibr12-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calver</surname><given-names>L.</given-names></name>
<name><surname>Dunlop</surname><given-names>A.J.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Individual patient assessment of methadone-induced QT prolongation with digital holter recording</article-title>. <source>J Addiction Med</source> <volume>6</volume>: <fpage>92</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr13-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>K.-C.</given-names></name>
<name><surname>Huang</surname><given-names>C.-L.</given-names></name>
<name><surname>Liang</surname><given-names>H.-Y.</given-names></name>
<name><surname>Chang</surname><given-names>S.-S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.-C.</given-names></name>
<name><surname>Liang</surname><given-names>W.-M.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence</article-title>. <source>J Cardiovasc Electrophysiol</source> <volume>23</volume>:<fpage>527</fpage>–<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr14-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chugh</surname><given-names>S.S.</given-names></name>
<name><surname>Socoteanu</surname><given-names>C.</given-names></name>
<name><surname>Reinier</surname><given-names>K.</given-names></name>
<name><surname>Waltz</surname><given-names>J.</given-names></name>
<name><surname>Jui</surname><given-names>J.</given-names></name>
<name><surname>Gunson</surname><given-names>K.</given-names></name>
</person-group> (<year>2008</year>) <article-title>A community-based evaluation of sudden death associated with therapeutic levels of methadone</article-title>. <source>Am J Med</source> <volume>121</volume>: <fpage>66</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr15-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crotti</surname><given-names>L.</given-names></name>
<name><surname>Hu</surname><given-names>D.</given-names></name>
<name><surname>Barajas-Martinez</surname><given-names>H.</given-names></name>
<name><surname>De Ferrari</surname><given-names>G.M.</given-names></name>
<name><surname>Oliva</surname><given-names>A.</given-names></name>
<name><surname>Insolia</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant</article-title>. <source>Heart Rhythm</source> <volume>9</volume>: <fpage>1104</fpage>–<lpage>1112</lpage>.</citation>
</ref>
<ref id="bibr16-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cruciani</surname><given-names>R.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Methadone: To ECG or not to ECG…that is still the question</article-title>. <source>J Pain Symptom Manage</source> <volume>36</volume>: <fpage>545</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr17-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Jong</surname><given-names>I.M.</given-names></name>
<name><surname>De Ruiter</surname><given-names>G.S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: a case report</article-title>. <source>Netherlands Heart J</source> Ahead of print <day>29</day> <month>January</month> <year>2011</year>:</citation>
</ref>
<ref id="bibr18-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deamer</surname><given-names>R.L.</given-names></name>
<name><surname>Wilson</surname><given-names>D.R.</given-names></name>
<name><surname>Clark</surname><given-names>D.S.</given-names></name>
<name><surname>Prichard</surname><given-names>J.G.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Torsades de pointes associated with high dose levomethadyl acetate (Orlaam®)</article-title>. <source>J Addictive Dis</source> <volume>20</volume>: <fpage>7</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr19-2045125312469982">
<citation citation-type="book">
<collab>Department of Health (England) and the Devolved Administrations</collab>. (<year>2007</year>) <source>Drug Misuse and Dependence: Uk Guidelines on Clinical Management</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive</publisher-name>.</citation>
</ref>
<ref id="bibr20-2045125312469982">
<citation citation-type="gov">
<collab>Drug and Alcohol Services Information System</collab>. (<year>2006</year> <ext-link ext-link-type="uri" xlink:href="http://www.oas.samhsa.gov/2k6/otp/otp.htm">http://www.oas.samhsa.gov/2k6/otp/otp.htm</ext-link>) <article-title>Facilities operating opioid treatment programs: 2005, The DASIS Report, Vol. 36</article-title>.</citation>
</ref>
<ref id="bibr21-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eap</surname><given-names>C.B.</given-names></name>
<name><surname>Crettol</surname><given-names>S.</given-names></name>
<name><surname>Rougier</surname><given-names>J.S.</given-names></name>
<name><surname>Schlapfer</surname><given-names>J.</given-names></name>
<name><surname>Sintra Grilo</surname><given-names>L.</given-names></name>
<name><surname>Deglon</surname><given-names>J.J.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Stereoselective block of herg channel by (s)-methadone and QT interval prolongation in Cyp2b6 slow metabolizers</article-title>. <source>Clin Pharmacol Ther</source> <volume>81</volume>: <fpage>719</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr22-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esses</surname><given-names>J.L.</given-names></name>
<name><surname>Rosman</surname><given-names>J.</given-names></name>
<name><surname>Do</surname><given-names>L.T.</given-names></name>
<name><surname>Schweitzer</surname><given-names>P.</given-names></name>
<name><surname>Hanon</surname><given-names>S.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes</article-title>. <source>J Interventional Cardiac Electrophysiol</source> <volume>23</volume>: <fpage>117</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr23-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Falconer</surname><given-names>M.</given-names></name>
<name><surname>Molloy</surname><given-names>D.</given-names></name>
<name><surname>Ingerhaug</surname><given-names>J.</given-names></name>
<name><surname>Barry</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Methadone induced torsade de pointes in a patient receiving antiretroviral therapy</article-title>. <source>Irish Med J</source> <volume>100</volume>: <fpage>631</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr24-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gil</surname><given-names>M.</given-names></name>
<name><surname>Sala</surname><given-names>M.</given-names></name>
<name><surname>Anguera</surname><given-names>I.</given-names></name>
<name><surname>Chapinal</surname><given-names>O.</given-names></name>
<name><surname>Cervantes</surname><given-names>M.</given-names></name>
<name><surname>Guma</surname><given-names>J.R.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>QT Prolongation and torsades de pointes in patients infected with human immunodeficiency virus and treated with methadone</article-title>. <source>Am J Cardiol</source> <volume>92</volume>: <fpage>995</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr25-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gintant</surname><given-names>G.A.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Preclinical torsades-de-pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk</article-title>. <source>Pharmacol Ther</source> <volume>119</volume>: <fpage>199</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr26-2045125312469982">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gleick</surname><given-names>J.</given-names></name>
</person-group> (<year>1987</year>) <article-title>Chaos: making a new science</article-title>. <publisher-loc>Viking</publisher-loc>: <publisher-name>New York</publisher-name>.</citation>
</ref>
<ref id="bibr27-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hancox</surname><given-names>J.C.</given-names></name>
<name><surname>Mcpate</surname><given-names>M.J.</given-names></name>
<name><surname>El Harchi</surname><given-names>A.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.H.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The Herg potassium channel and Herg screening for drug-induced torsades de pointes</article-title>. <source>Pharmacol Ther</source> <volume>119</volume>: <fpage>118</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr28-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanon</surname><given-names>S.</given-names></name>
<name><surname>Seewald</surname><given-names>R.M.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Schweitzer</surname><given-names>P.</given-names></name>
<name><surname>Rosman</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Ventricular arrhythmias in patients treated with methadone for opioid dependence</article-title>. <source>J Interventional Cardiac Electrophysiol</source> <volume>28</volume>: <fpage>19</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr29-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hussain</surname><given-names>T.</given-names></name>
<name><surname>Ewer</surname><given-names>A.K.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Maternal methadone may cause arrhythmias in neonates</article-title>. <source>Acta Paediatrica</source> <volume>96</volume>: <fpage>768</fpage>–<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr30-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iskandar</surname><given-names>S.B.</given-names></name>
<name><surname>Abi-Saleh</surname><given-names>B.S.</given-names></name>
<name><surname>Mechleb</surname><given-names>B.K.</given-names></name>
<name><surname>Fahrig</surname><given-names>S.A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Methadone and torsade de pointes: case report and review of the literature</article-title>. <source>Tennessee Med</source> <volume>100</volume>: <fpage>35</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr31-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>John</surname><given-names>J.</given-names></name>
<name><surname>Amley</surname><given-names>X.</given-names></name>
<name><surname>Bombino</surname><given-names>G.</given-names></name>
<name><surname>Gitelis</surname><given-names>C.</given-names></name>
<name><surname>Topi</surname><given-names>B.</given-names></name>
<name><surname>Hollander</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Torsade de pointes due to methadone use in a patient with hiv and hepatitis C coinfection</article-title>. <source>Cardiol Res Practice</source> <volume>2010</volume>: <fpage>524764</fpage>.</citation>
</ref>
<ref id="bibr32-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Rampe</surname><given-names>D.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels</article-title>. <source>Eur J Pharmacol</source> <volume>458</volume>: <fpage>25</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr33-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katchman</surname><given-names>A.N.</given-names></name>
<name><surname>Koerner</surname><given-names>J.</given-names></name>
<name><surname>Tosaka</surname><given-names>T.</given-names></name>
<name><surname>Woosley</surname><given-names>R.L.</given-names></name>
<name><surname>Ebert</surname><given-names>S.N.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Comparative evaluation of herg currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs</article-title>. <source>J Pharmacol Exp Ther</source> <volume>316</volume>: <fpage>1098</fpage>–<lpage>1106</lpage>.</citation>
</ref>
<ref id="bibr34-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katchman</surname><given-names>A.N.</given-names></name>
<name><surname>Mcgroary</surname><given-names>K.A.</given-names></name>
<name><surname>Kilborn</surname><given-names>M.J.</given-names></name>
<name><surname>Kornick</surname><given-names>C.A.</given-names></name>
<name><surname>Manfredi</surname><given-names>P.L.</given-names></name>
<name><surname>Woosley</surname><given-names>R.L.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents</article-title>. <source>J Pharmacol Exp Ther</source> <volume>303</volume>: <fpage>688</fpage>–<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr35-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kornick</surname><given-names>C.A.</given-names></name>
<name><surname>Kilborn</surname><given-names>M.J.</given-names></name>
<name><surname>Santiago-Palma</surname><given-names>J.</given-names></name>
<name><surname>Schulman</surname><given-names>G.</given-names></name>
<name><surname>Thaler</surname><given-names>H.T.</given-names></name>
<name><surname>Keefe</surname><given-names>D.L.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>QTc interval prolongation associated with intravenous methadone</article-title>. <source>Pain</source> <volume>105</volume>: <fpage>499</fpage>–<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr36-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Garcia</surname><given-names>J.A.</given-names></name>
<name><surname>Mehler</surname><given-names>P.S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes</article-title>. <source>Pharmacother</source> <volume>25</volume>: <fpage>611</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr37-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Kutinsky</surname><given-names>I.B.</given-names></name>
<name><surname>Robertson</surname><given-names>A.D.</given-names></name>
<name><surname>Mehler</surname><given-names>P.S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes</article-title> <source>Pharmacother</source> <volume>23</volume>: <fpage>802</fpage>–<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr38-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Lewkowiez</surname><given-names>L.</given-names></name>
<name><surname>Hays</surname><given-names>H.</given-names></name>
<name><surname>Woodroffe</surname><given-names>M.A.</given-names></name>
<name><surname>Robertson</surname><given-names>A.D.</given-names></name>
<name><surname>Mehler</surname><given-names>P.S.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Torsade de pointes associated with very-high-dose methadone</article-title>. <source>Ann Intern Med</source> <volume>137</volume>: <fpage>501</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr39-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Lowery</surname><given-names>C.M.</given-names></name>
<name><surname>Martell</surname><given-names>B.A.</given-names></name>
<name><surname>Gourevitch</surname><given-names>M.N.</given-names></name>
<name><surname>Arnsten</surname><given-names>J.H.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Effects of methadone on Qt-interval dispersion</article-title>. <source>Pharmacother</source> <volume>25</volume>: <fpage>1523</fpage>–<lpage>1529</lpage>.</citation>
</ref>
<ref id="bibr40-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Rowan</surname><given-names>S.B.</given-names></name>
<name><surname>Mehler</surname><given-names>P.S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cocaine-related torsade de pointes in a methadone maintenance patient</article-title>. <source>J Addictive Dis</source> <volume>24</volume>: <fpage>53</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr41-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuryshev</surname><given-names>Y.A.</given-names></name>
<name><surname>Bruening-Wright</surname><given-names>A.</given-names></name>
<name><surname>Brown</surname><given-names>A.M.</given-names></name>
<name><surname>Kirsch</surname><given-names>G.E.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels</article-title>. <source>J Cardiovasc Pharmacol</source> <volume>56</volume>: <fpage>420</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr42-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Somberg</surname><given-names>T.</given-names></name>
<name><surname>Molnar</surname><given-names>J.</given-names></name>
<name><surname>Somberg</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The effects of chiral isolates of methadone on the cardiac potassium channel Ikr</article-title>. <source>Cardiology</source> <volume>113</volume>: <fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr43-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lüthi</surname><given-names>B.</given-names></name>
<name><surname>Huttner</surname><given-names>A.</given-names></name>
<name><surname>Speck</surname><given-names>R.F.</given-names></name>
<name><surname>Mueller</surname><given-names>N.J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Methadone-induced torsade de pointes after stopping lopinavir-ritonavir</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> <volume>26</volume>: <fpage>367</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr44-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magnano</surname><given-names>A.R.</given-names></name>
<name><surname>Talathoti</surname><given-names>N.B.</given-names></name>
<name><surname>Hallur</surname><given-names>R.</given-names></name>
<name><surname>Jurus</surname><given-names>D.T.</given-names></name>
<name><surname>Dizon</surname><given-names>J.</given-names></name>
<name><surname>Holleran</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Effect of acute cocaine administration on the QTc interval of habitual users</article-title>. <source>Am J Cardiol</source> <volume>97</volume>: <fpage>1244</fpage>–<lpage>1246</lpage>.</citation>
</ref>
<ref id="bibr45-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makkar</surname><given-names>R.R.</given-names></name>
<name><surname>Fromm</surname><given-names>B.S.</given-names></name>
<name><surname>Steinman</surname><given-names>R.T.</given-names></name>
<name><surname>Meissner</surname><given-names>M.D.</given-names></name>
<name><surname>Lehmann</surname><given-names>M.H.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs</article-title>. <source>J Am Med Assoc</source> <volume>270</volume>: <fpage>2590</fpage>–<lpage>2597</lpage>.</citation>
</ref>
<ref id="bibr46-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mantelli</surname><given-names>L.</given-names></name>
<name><surname>Corti</surname><given-names>V.</given-names></name>
<name><surname>Bini</surname><given-names>R.</given-names></name>
<name><surname>Cerbai</surname><given-names>E.</given-names></name>
<name><surname>Ledda</surname><given-names>F.</given-names></name>
</person-group> (<year>1986</year>) <article-title>[Effects of Dl-methadone on the response to physiological transmitters and on several functional parameters of the isolated guinea-pig heart]</article-title>. <source>Archives Internationales de Pharmacodynamie et de Therapie</source> <volume>282</volume>: <fpage>298</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr47-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maremmani</surname><given-names>I.</given-names></name>
<name><surname>Pacini</surname><given-names>M.</given-names></name>
<name><surname>Cesaroni</surname><given-names>C.</given-names></name>
<name><surname>Lovrecic</surname><given-names>M.</given-names></name>
<name><surname>Perugi</surname><given-names>G.</given-names></name>
<name><surname>Tagliamonte</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>QTc interval prolongation in patients on long-term methadone maintenance therapy</article-title>. <source>Eur Addiction Res</source> <volume>11</volume>: <fpage>44</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr48-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martell</surname><given-names>B.A.</given-names></name>
<name><surname>Arnsten</surname><given-names>J.H.</given-names></name>
<name><surname>Krantz</surname><given-names>M.J.</given-names></name>
<name><surname>Gourevitch</surname><given-names>M.N.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Impact of methadone treatment on cardiac repolarization and conduction in opioid users</article-title>. <source>Am J Cardiol</source> <volume>95</volume>: <fpage>915</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr49-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miceli</surname><given-names>J.J.</given-names></name>
<name><surname>Tensfeldt</surname><given-names>T.G.</given-names></name>
<name><surname>Shiovitz</surname><given-names>T.</given-names></name>
<name><surname>Anziano</surname><given-names>R.</given-names></name>
<name><surname>O’gorman</surname><given-names>C.</given-names></name>
<name><surname>Harrigan</surname><given-names>R.H.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder</article-title>. <source>Pharmacother: J Hum Pharmacol Drug Ther</source> <volume>30</volume>: <fpage>127</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr50-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nair</surname><given-names>M.K.</given-names></name>
<name><surname>Patel</surname><given-names>K.</given-names></name>
<name><surname>Starer</surname><given-names>P.J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Ciprofloxacin-Induced torsades de pointes in a methadone-dependent patient</article-title>. <source>Addiction</source> <volume>103</volume>: <fpage>2062</fpage>–<lpage>2064</lpage>.</citation>
</ref>
<ref id="bibr51-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noorzurani</surname><given-names>M.H.</given-names></name>
<name><surname>Vicknasingam</surname><given-names>B.</given-names></name>
<name><surname>Narayanan</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy</article-title>. <source>Drug Alcohol Rev</source> <volume>28</volume>: <fpage>688</fpage>–<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr52-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordt</surname><given-names>S.P.</given-names></name>
<name><surname>Zilberstein</surname><given-names>J.</given-names></name>
<name><surname>Gold</surname><given-names>B.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Methadone-induced torsade de pointes</article-title>. <source>Am J Emergency Med</source> <volume>29</volume>: <fpage>476.e471</fpage>–<lpage>476.e472</lpage>.</citation>
</ref>
<ref id="bibr53-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pimentel</surname><given-names>L.</given-names></name>
<name><surname>Mayo</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Chronic methadone therapy complicated by torsades de pointes: a case report</article-title>. <source>J Emergency Med</source> <volume>34</volume>: <fpage>287</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr54-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prosser</surname><given-names>J.M.</given-names></name>
<name><surname>Mills</surname><given-names>A.</given-names></name>
<name><surname>Rhim</surname><given-names>E.S.</given-names></name>
<name><surname>Perrone</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Torsade de pointes caused by polypharmacy and substance abuse in a patient with human immunodeficiency virus</article-title>. <source>Int J Emergency Med</source> <volume>1</volume>: <fpage>217</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr55-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Puri</surname><given-names>R.</given-names></name>
<name><surname>Roberts-Thomson</surname><given-names>K.C.</given-names></name>
<name><surname>Young</surname><given-names>G.D.</given-names></name>
</person-group> (<year>2009</year>) <article-title>HIV and long QT syndrome—cause or coincidence</article-title>. <source>Int J Cardiol</source> <volume>133</volume>: <fpage>e9</fpage>–<lpage>e10</lpage>.</citation>
</ref>
<ref id="bibr56-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raschi</surname><given-names>E.</given-names></name>
<name><surname>Ceccarini</surname><given-names>L.</given-names></name>
<name><surname>De Ponti</surname><given-names>F.</given-names></name>
<name><surname>Recanatini</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Herg-related drug toxicity and models for predicting herg liability and QT prolongation</article-title>. <source>Exp Opin Drug Metab Toxicol</source> <volume>5</volume>: <fpage>1005</fpage>–<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr57-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Redfern</surname><given-names>W.S.</given-names></name>
<name><surname>Carlsson</surname><given-names>L.</given-names></name>
<name><surname>Davis</surname><given-names>A.S.</given-names></name>
<name><surname>Lynch</surname><given-names>W.G.</given-names></name>
<name><surname>Mackenzie</surname><given-names>I.</given-names></name>
<name><surname>Palethrope</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Relationship between preclinical electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug devleopment</article-title>. <source>Cardiovasc Res</source> <volume>58</volume>: <fpage>32</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr58-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reinhold</surname><given-names>J.A.</given-names></name>
<name><surname>Sanoski</surname><given-names>C.A.</given-names></name>
<name><surname>Russo</surname><given-names>A.M.</given-names></name>
<name><surname>Cooper</surname><given-names>J.M.</given-names></name>
<name><surname>Spinler</surname><given-names>S.A.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Torsades de pointes associated with methadone and voriconazole</article-title>. <source>Br Med J Case Reports</source> Epub <year>2009</year> <month>December</month> <day>22</day>:</citation>
</ref>
<ref id="bibr59-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Routhier</surname><given-names>D.D.</given-names></name>
<name><surname>Katz</surname><given-names>K.D.</given-names></name>
<name><surname>Brooks</surname><given-names>D.E.</given-names></name>
</person-group> (<year>2007</year>) <article-title>QTc prolongation and torsades de pointes associated with methadone therapy</article-title>. <source>J Emergency Med</source> <volume>32</volume>: <fpage>275</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr60-2045125312469982">
<citation citation-type="journal">
<collab>Roxane Laboratories</collab>. (<year>2003</year>) <article-title>Dolphine hydrochloride (methadone hydrochloride tablets) package insert</article-title>.</citation>
</ref>
<ref id="bibr61-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roy</surname><given-names>A.K.</given-names></name>
<name><surname>Mccarthy</surname><given-names>C.</given-names></name>
<name><surname>Kiernan</surname><given-names>G.</given-names></name>
<name><surname>Mcgorrian</surname><given-names>C.</given-names></name>
<name><surname>Keenan</surname><given-names>E.</given-names></name>
<name><surname>Mahon</surname><given-names>N.G.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy</article-title>. <source>Addiction</source> <volume>107</volume>: <fpage>1132</fpage>–<lpage>1139</lpage>.</citation>
</ref>
<ref id="bibr62-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanguinetti</surname><given-names>M.C.</given-names></name>
<name><surname>Jiang</surname><given-names>C.</given-names></name>
<name><surname>Curran</surname><given-names>M.E.</given-names></name>
<name><surname>Keating</surname><given-names>M.T.</given-names></name>
</person-group> (<year>1995</year>) <article-title>A mechanistic link between an inherited and an acquired cardiac arrhythmia: herg encodes the Ikr potassium channel</article-title>. <source>Cell</source> <volume>81</volume>: <fpage>299</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr63-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanguinetti</surname><given-names>M.C.</given-names></name>
<name><surname>Mitcheson</surname><given-names>J.S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Predicting drug-Herg channel interactions that cause acquired long QT syndrome</article-title>. <source>Trend Pharmacol Sci</source> <volume>26</volume>: <fpage>119</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr64-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sekine</surname><given-names>R.</given-names></name>
<name><surname>Obbens</surname><given-names>E.a.M.T.</given-names></name>
<name><surname>Coyle</surname><given-names>N.</given-names></name>
<name><surname>Inturrisi</surname><given-names>C.E.</given-names></name>
</person-group> (<year>2007</year>) <article-title>The successful use of parenteral methadone in a patient with a prolonged QTc interval</article-title>. <source>J Pain Symptom Manage</source> <volume>34</volume>: <fpage>566</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr65-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sticherling</surname><given-names>C.</given-names></name>
<name><surname>Schaer</surname><given-names>B.A.</given-names></name>
<name><surname>Ammann</surname><given-names>P.</given-names></name>
<name><surname>Maeder</surname><given-names>M.</given-names></name>
<name><surname>Osswald</surname><given-names>S.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Methadone-induced torsade de pointes tachycardias</article-title>. <source>Swiss Medical Weekly</source> <volume>135</volume>: <fpage>282</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr66-2045125312469982">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Taleb</surname><given-names>N.N.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The black swan</article-title>, <edition>2nd Edition.</edition> <publisher-loc>Random House</publisher-loc>: <publisher-name>New York</publisher-name>.</citation>
</ref>
<ref id="bibr67-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thanavaro</surname><given-names>K.L.</given-names></name>
<name><surname>Thanavaro</surname><given-names>J.L.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Methadone–induced torsades de pointes: a twist of fate</article-title>. <source>Heart Lung: J Acute Crit Care</source> <volume>40</volume>: <fpage>448</fpage>–<lpage>453</lpage>.</citation>
</ref>
<ref id="bibr68-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trudeau</surname><given-names>M.C.</given-names></name>
<name><surname>Warmke</surname><given-names>J.W.</given-names></name>
<name><surname>Ganetzky</surname><given-names>B.</given-names></name>
<name><surname>Robertson</surname><given-names>G.A.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Herg, a human inward rectifier in the voltage-gated potassium channel family</article-title>. <source>Science</source> <volume>269</volume>: <fpage>92</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr69-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.</given-names></name>
<name><surname>Hasnain</surname><given-names>M.</given-names></name>
<name><surname>Howland</surname><given-names>R.H.</given-names></name>
<name><surname>Hettema</surname><given-names>J.M.</given-names></name>
<name><surname>Kogut</surname><given-names>C.</given-names></name>
<name><surname>Wood</surname><given-names>M.A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Citalopram, QTc interval prolongation and torsade de pointes. how should we apply the recent FDA ruling?</article-title> <source>Am J Med</source> <volume>125</volume>: <fpage>859</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr70-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.R.</given-names></name>
</person-group> (<year>2003</year>) <article-title>New generation antipsychotic drugs and QTc interval prolongation</article-title>. <source>Prim Care Comp J Clin Psychiatry</source> <volume>5</volume>: <fpage>205</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr71-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.R.</given-names></name>
<name><surname>Hasnain</surname><given-names>M.</given-names></name>
<name><surname>Wood</surname><given-names>M.A.</given-names></name>
<name><surname>Fernandez</surname><given-names>A.</given-names></name>
<name><surname>Lesnefsky</surname><given-names>E.J.</given-names></name>
<name><surname>Pandurangi</surname><given-names>A.K.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Cardiometabolic risks of antidepressant and antipsychotic drugs, part 1. proarrhythmic risks of antidepressant and antipsychotic drugs</article-title>. <source>Psychiatric Times</source> <volume>28</volume> (<month>April</month>): <fpage>50</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr72-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.R.</given-names></name>
<name><surname>Schneider</surname><given-names>R.K.</given-names></name>
<name><surname>Wood</surname><given-names>M.A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>112</volume>: <fpage>319</fpage>–<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr73-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.R.</given-names></name>
<name><surname>Wood</surname><given-names>M.A.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Tricyclic antidepressants, QT interval prolongation and torsade de pointes</article-title> <source>Psychosomatics</source> <volume>45</volume>: <fpage>371</fpage>–<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr74-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vieweg</surname><given-names>W.V.R.</given-names></name>
<name><surname>Wood</surname><given-names>M.A.</given-names></name>
<name><surname>Fernandez</surname><given-names>A.</given-names></name>
<name><surname>Beatty-Brooks</surname><given-names>M.</given-names></name>
<name><surname>Hasnain</surname><given-names>M.</given-names></name>
<name><surname>Pandurangi</surname><given-names>A.K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly</article-title>. <source>Drugs Aging</source> <volume>26</volume>: <fpage>997</fpage>–<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr75-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viskin</surname><given-names>S.</given-names></name>
<name><surname>Justo</surname><given-names>D.</given-names></name>
<name><surname>Halkin</surname><given-names>A.</given-names></name>
<name><surname>Zeltser</surname><given-names>D.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Long QT syndrome caused by noncardiac drugs</article-title>. <source>Progress in Cardiovascular Diseases</source> <volume>45</volume>: <fpage>415</fpage>–<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr76-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vodoz</surname><given-names>J.F.</given-names></name>
<name><surname>Jaquier</surname><given-names>F.</given-names></name>
<name><surname>Lamy</surname><given-names>O.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone</article-title>. <source>Praxis (Bern 1994)</source> <volume>92</volume>: <fpage>1748</fpage>–<lpage>1750</lpage>.</citation>
</ref>
<ref id="bibr77-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walker</surname><given-names>P.W.</given-names></name>
<name><surname>Klein</surname><given-names>D.</given-names></name>
<name><surname>Kasza</surname><given-names>L.</given-names></name>
</person-group> (<year>2003</year>) <article-title>High dose methadone and ventricular arrhythmias: a report of three cases</article-title>. <source>Pain</source> <volume>103</volume>: <fpage>321</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr78-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witchel</surname><given-names>H.J.</given-names></name>
<name><surname>Hancox</surname><given-names>J.C.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current</article-title>. <source>Clin Exp Pharmacol Physiol</source> <volume>27</volume>: <fpage>753</fpage>–<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr79-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Roberts</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Case files of the drexel university medical toxicology fellowship: methadone-induced QTc prolongation</article-title>. <source>J Med Toxicol</source> <volume>3</volume>: <fpage>190</fpage>–<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr80-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zeltser</surname><given-names>D.</given-names></name>
<name><surname>Justo</surname><given-names>D.</given-names></name>
<name><surname>Halkin</surname><given-names>A.</given-names></name>
<name><surname>Prokhorov</surname><given-names>V.</given-names></name>
<name><surname>Heller</surname><given-names>K.</given-names></name>
<name><surname>Viskin</surname><given-names>S.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Torsade de pointes due to noncardiac drugs. most patients have easily identifiable risk factors</article-title>. <source>Medicine</source> <volume>82</volume>: <fpage>282</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr81-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zickler</surname><given-names>P.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Gender differences in prevalence of drug abuse traced to opportunities to use</article-title>. <source>NIDA Notes 15 Number</source> <volume>4</volume>: <fpage>1</fpage>–<lpage>2</lpage>.</citation>
</ref>
<ref id="bibr82-2045125312469982">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zunkler</surname><given-names>B.J.</given-names></name>
<name><surname>Wos-Maganga</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Comparison of the effects of methadone and heroin on Human ether-a-go-go-related gene channels</article-title>. <source>Cardiovasc Toxicol</source> <volume>10</volume>: <fpage>161</fpage>–<lpage>165</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>